Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial

RCT (n=95; Japan) found maintenance of remission was significantly more common in patients who continued infliximab than in those who discontinued (of 92 patients, 37 [80.4%] vs 25 [54.3%], respectively, in remission at week 48. p=0.0076).

Source:

The Lancet Gastroenterology and Hepatology